Ingenix is building an AI Co-pilot for generating real-time hypotheses on clinical endpoints values and adverse events.
Ingenix has raised $15.1M in total funding. The most recent round was Seed. The last funding was announced in June 2026.
Ingenix's investors include OTB Ventures, Inovo.vc, Sofinnova Partners, IFC Venture Capital Group.
Ingenix is headquartered in Warsaw, Poland.
Ingenix is building an AI Co-pilot for generating real-time hypotheses on clinical endpoints values and adverse events.
Ingenix is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Ingenix — Funding & Investors." VCBacked, June 3, 2026, https://www.vcbacked.co/company/ingenix. Accessed September 16, 2026.
VCBacked. (2026). Ingenix — Funding & Investors. Retrieved September 16, 2026, from https://www.vcbacked.co/company/ingenix
{{cite web |title=Ingenix — Funding & Investors |url=https://www.vcbacked.co/company/ingenix |website=VCBacked |access-date=September 16, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated